PolyPeptide Group AG (0AAJ.L) Comparison with companies in other sectors?

PolyPeptide Group AG has a share price of 32.85M. You can analyze PolyPeptide Group AG (0AAJ.L) competitors across different market sectors through stock heatmaps.

What are 0AAJ.L's NET and operating margins?

PolyPeptide Group AG (0AAJ.L) operating margin is around -0.02, and net profit margin is approximately -0.06 as of the latest reports.

In what way does 0AAJ.L's earnings per share (EPS) trend reflect its financial momentum?

PolyPeptide Group AG (0AAJ.L) EPS is 1.50 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for PolyPeptide Group AG is 15.07, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for PolyPeptide Group AG?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for PolyPeptide Group AG like P/E which is -40.93, P/B which is 2.24, and PEG which is -0.38. Compare them with sector averages to evaluate if the stock is priced fairly.

PolyPeptide Group AG

0AAJ.L•LSE

Healthcare

Biotechnology

£21.75

£-1.15(-5.02%)

PolyPeptide Group AG (0AAJ.L) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$1.50

P/E Ratio

15.07

ROE

-0.05%

Net Margin

-0.06%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$744.07M

Shares OutstandingTotal number of shares issued

$32.85M

Book Value/ShareNet worth per share

$10.85

Revenue/ShareAnnual revenue per share

$10.28

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.496

Net MarginNet income as percentage of revenue

-5.78%

Operating MarginOperating income as percentage of revenue

-2.17%

ROEReturn on shareholders' equity

-5.30%

ROAReturn on total assets

-2.59%

ROCEReturn on capital employed

-1.31%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.07

Cash/ShareCash and equivalents per share

$2.07

FCF YieldFree cash flow as percentage of market cap

0.30%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 0AAJ.LFinancial Ratios Analysis details for 0AAJ.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 0AAJ.LSector Benchmarking details for 0AAJ.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for PolyPeptide Group AG Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of PolyPeptide Group AG. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account PolyPeptide Group AG's unique business strengths and challenges.

Key Financial Metrics for PolyPeptide Group AG

For PolyPeptide Group AG, essential financial indicators include EPS 1.50, PE 15.07, and ROE -0.05. These key ratios reveal insights into PolyPeptide Group AG's profitability, valuation, and operational health. Understanding these metrics enables you to compare PolyPeptide Group AG with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of PolyPeptide Group AG

Metrics like Net Margin -5.78% and ROA -2.59% shed light on how well PolyPeptide Group AG is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether PolyPeptide Group AG can sustain its operations and continue growing in the future.

Valuation and Market Position of PolyPeptide Group AG

Using ratios such as P/B Ratio 2.24 and PEG Ratio -0.38, investors can assess whether PolyPeptide Group AG is appropriately valued based on its financials and growth potential. These figures, combined with PolyPeptide Group AG's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for PolyPeptide Group AG

Financial health indicators, such as Debt/Equity Ratio 0.26 and Cash Flow $0.07, provide a snapshot of PolyPeptide Group AG's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like PolyPeptide Group AG, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for PolyPeptide Group AG

Investing in PolyPeptide Group AG based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at PolyPeptide Group AG focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;